SAFETY AND TOLERABILITY OF SUBCUTANEOUS TRASTUZUMAB AS A TREATMENT IN PATIENTS WITH EARLY HER 2 POSITIVE BREAST CANCER : EXPERIENCE OF A CANCER CENTER IN PERU

被引：0
|
作者：
Otoya, Iris
Valdivieso, Natalia
Morante, Zaida
Castaneda, Carlos
Neciosup, Silvia
Calderon, Monica
Gomez, Henry
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-17-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-17-08
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
    Otoya, Iris
    Valdiviezo, Natalia
    Morante, Zaida
    Calle, Cindy
    Ferreyra, Yomali
    Huarcaya-Chombo, Norma
    Polo-Mendoza, Gabriela
    Castaneda, Carlos
    Vidaurre, Tatiana
    Neciosup, Silvia P.
    Calderon, Monica J.
    Gomez, Henry L.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
  • [2] BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer
    Cocquyt, V. F.
    Martinez-Mena, C. L.
    Martens, M. T.
    D'Hondt, R. G.
    Graas, M-P L.
    Evron, E.
    Fried, G.
    Ben-Baruch, N. E.
    Dijkstra, A. C.
    Van De Walle, E. I.
    CANCER RESEARCH, 2017, 77
  • [3] Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study
    Wong, Chi Yan
    Leung, Roland
    Kwok, Gin Wai
    Tsang, Josephine
    Li, Bryan
    Yau, Thomas
    Chiu, Joanne
    POSTGRADUATE MEDICAL JOURNAL, 2022, 98 (1163) : 666 - 669
  • [4] Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience
    Mukku, R. B.
    Verma, S.
    Liu, J.
    Steingart, R.
    Hudis, C.
    Yu, A. F.
    Dang, C.
    CANCER RESEARCH, 2016, 76
  • [5] Cardiac safety of trastuzumab without an anthracycline in patients with HER2-positive early stage breast cancer: A single center experience
    Mukku, R. B.
    Verma, S.
    Liu, J.
    Steingart, R.
    Hudis, C.
    Yu, A. F.
    Dang, C.
    CANCER RESEARCH, 2016, 76
  • [6] Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer
    Melichar, Bohuslav
    Studentova, Hana
    Kalabova, Hana
    Vitaskova, Denisa
    IMMUNOTHERAPY, 2014, 6 (07) : 811 - 819
  • [7] Subcutaneous trastuzumab - recent evidence on efficacy and safety in HER2-positive breast cancer patients
    Pogoda, Katarzyna
    Niwinska, Anna
    ONCOLOGY IN CLINICAL PRACTICE, 2015, 11 (02): : 93 - 99
  • [8] Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
    Hamizi, Salima
    Freyer, Gilles
    Bakrin, Naoual
    Henin, Emilie
    Mohtaram, Amina
    Le Saux, Olivia
    Falandry, Claire
    ONCOTARGETS AND THERAPY, 2013, 6 : 89 - 94
  • [9] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Heo, Young-A
    Syed, Yahiya Y.
    TARGETED ONCOLOGY, 2019, 14 (06) : 749 - 758
  • [10] Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
    Young-A Heo
    Yahiya Y. Syed
    Targeted Oncology, 2019, 14 : 749 - 758
12345